Newsroom

victoria, british columbia (canada), march 28, 2024 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), intersystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with immunoprecise antibodies ltd. (ipa) (nasdaq: ipa), an artificial intelligence-driven biotherapeutic research and technology company, are thrilled to announce a landmark collaboration. this collaboration integrates the new vector search capability of the intersystems iris® data platform with ipa’s subsidiary biostrand's lensai platform, setting a new standard for ai-driven applications in healthcare and life sciences. this collaboration signifies a leap in technological advancement for addressing challenges with increasing volumes of data that the healthcare and life sciences industries are contending with today. with the global ai market projected to grow to over $1.3 trillion by 2032, the collaboration between intersystems and ipa highlights both companies' commitment to innovation, excellence, and the development of solutions that not only meet the current needs of the healthcare and life sciences sectors but also anticipate future challenges, with additional client solutions and developments expected as vector search and lensai redefine the interaction between data and ai applications in healthcare and life sciences. “as the latest addition to the intersystems iris data platform, vector search has helped to supercharge the identification and creation of novel drug compounds, significantly reducing r&d timelines from development to commercialization” said scott gnau, head of global data platforms at intersystems. “we look forward to seeing how vector search within intersystems iris empowers other developers to build additional ai applications on our platform.” "by combining intersystem’s vector search with ipa's lensai, we're empowering developers and researchers in the life sciences with unparalleled tools for extracting value and insights from complex datasets, driving forward the potential for ai in every application within the healthcare and life sciences sectors," said dirk van hyfte md, phd, co-founder and head of innovation of biostrand. "we are at the cusp of a new era in ai-driven applications, where the integration of sophisticated data analysis tools like vector search with the deep biological insights provided by lensai can lead to breakthroughs in patient care and treatment methodologies.” vector search and lensai: a synergistic integration this innovative integration marries the precision of vector search, which enables efficient and accurate retrieval of relevant information from massive datasets using vector embeddings, with the depth of analysis provided by lensai universal foundation ai model and biostrand's patented hyft technology. the result is a platform that offers unmatched capabilities in accessing, analyzing, and leveraging complex biological data for drug discovery, understanding disease mechanisms, and beyond. advancing healthcare and life sciences the collaboration between intersystems and ipa leverages the strengths of both platforms to offer several transformative benefits: precision and depth in data analysis: the integration enables more precise, semantically rich searches across vast repositories of unstructured biological data, uncovering insights that were previously difficult to obtain. accelerated drug discovery and development: researchers can now leverage the combined power of vector search and lensai to identify novel therapeutic targets more quickly, streamlining the drug discovery process and reducing the time from discovery to clinical trials. enhanced integration and scalability: by providing lensai capabilities within the intersystems iris data platform, companies in healthcare and life sciences gain a tool that seamlessly integrates with their existing infrastructure, offering scalability and enhanced performance without compromising security. about intersystems intersystems is a leading provider of next-generation solutions for enterprise digital transformations in the healthcare, finance, manufacturing, and supply chain sectors. its cloud-first data platforms solve interoperability, speed, and scalability problems for large organizations around the globe. intersystems offers a range of software, including its flagship data platform software, intersystems iris, and a set of industry specific applications that speed and simplify the process of making data “ai ready.” intersystems is committed to excellence through its award-winning, 24×7 support for customers and partners in more than 80 countries. privately held and headquartered in cambridge, massachusetts, intersystems was established in 1978 and now has 39 offices in 28 countries worldwide. for more information, please visit intersystems.com. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the market, the life sciences, drug discovery and development, healthcare, integration and / or success of lensai with vector search, or hyft technologies, including their benefits, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology and vector search may not have the expected results, risks that the expected healthcare benefits won't be achieved, in addition actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

ipa’s project revenue increased by 16.7% compared to the prior year, driven by the growth of the company's proprietary b cell select® platform and protein manufacturing services. talem therapeutics has announced a collaboration with libera bio to develop multi-target antibodies including the use of artificial intelligence (ai) technology. the companies will use talem's ai platform to help discover and optimize antibodies for various diseases, including cancer. this collaboration is expected to generate antibodies against disease targets that have historically been undruggable. briacell’s ai-based drug discovery program, after a brief pause due to additional workflows added, is underway and going well. the program is using biostrand’s lensai to analyze and prioritize potential drug targets for cancer treatment. briacell aims to use this technology to accelerate the development of new cancer therapies. biostrand announces the first monetization of its natural language processing (nlp) and immunogenicity modules. these modules are now allowing pharmaceutical companies to extract and analyze data from scientific publications and identify potential immunogenicity issues with drug candidates. biostrand is ramping its efforts to use this technology to help pharmaceutical companies develop safer and more effective drugs. biostrand's saas-based data management platform has been awarded a first-round rfp (request for proposal) by an undisclosed pharmaceutical company. the platform allows researchers to store, manage, and analyze large amounts of genomic, transcriptomic, and proteomic data using ai and hyfts technology. if awarded, this program is expected to help the pharmaceutical company accelerate its drug discovery process and improve its r&d efficiency. minimally, this third-party validation marks the beginning of a new potential revenue stream of great interest and high conceivable revenues for biostrand. victoria, british columbia (canada), march 16, 2023 – ipa (immunoprecise antibodies ltd.) (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today announced financial results for third quarter fiscal year 2023, which ended january 31, 2023. “we are thrilled to announce that this quarter has been a foundational one for our company. our project revenue has experienced a significant increase, thanks to our recognized best-in-class platform of function-first b cell. in addition, our clients have shown a noticeable trend of moving away from transgenic animals, which may limit genetic diversity of outputs, and towards animals with diverse b cell repertoires and rapid, cost-effective next-generation humanization technologies – capabilities that ipa is again unique positioned to provide”, stated dr. jennifer bath, ceo of ipa. she added, “in addition to our established success, we have ventured into the promising field of modern artificial intelligence, expanding our revenue streams, and providing the first revenue for our subsidiary, biostrand. our newest, unique ai-powered research collaboration may also allow us to tackle previously undruggable targets within the cellular context, and we are excited about the unparalleled value proposition that this could offer our investors. we are equally excited about our ongoing efforts to finalize another ai-driven research collaboration for a complex oncology program with a leading global oncology therapeutics company. these strategic initiatives have been critical in driving growth, innovation, and shareholder value, and we remain confident in our ability to continue to deliver exceptional results. as a company, we are proud of our achievements, and we look forward to the continued success that these initiatives will bring.” third quarter fiscal year 2023 financial summary* (all comparisons are to the period ended january 31, 2022) ipa achieved revenue of $5.2 million during the three months ended january 31, 2023, an increase of 7.4% compared to the three months ended january 31, 2022. project revenue increased 16.7% compared to the prior year. for the nine months ended january 31, 2023, total revenue growth of 10.9% when adjusting for the effect of currency translations. gross profit increased 14.6% to $3.0 million for the three months ended january 31, 2023 as compared to the same period last year. ipa held cash of $11.4 million as of january 31, 2023. *expressed in canadian dollars, unless otherwise indicated. financial results revenue & gross profit ipa achieved revenue of $5.2 million during the three months ended january 31, 2023, a 7.4% increase from the three months ended january 31, 2022. project revenue increased 16.7% compared to the prior year, driven by growth in the company’s b cell select® platform and protein manufacturing services. gross profit increased 14.6% to $3.0 million from the same period last year. liquidity and capital resources as of january 31, 2023, ipa held $11.4 million of cash, as compared to $30.0 million as of april 30, 2022, and had working capital of $12.2 million. ipa does not hold cash at silicon valley bank and has not seen any impact on our business from the collapse and subsequent take-over of the bank. polytope® taxt-03 antibody combination therapy talem, ipa's subsidiary, has experienced unanticipated delays in the production of its anti-covid therapeutic drug product, polytope, and has adjusted its milestones accordingly, having yet to receive the drug product from its cdmo partner, chempartner. talem is working closely with chempartner to negotiate a mutually beneficial outcome. due to these circumstances, the decision has been made to significantly reduce further investment in talem's covid program, while still recognizing the ongoing significance of covid-19 globally. ipa will continue to provide updates on talem's progress with chempartner and appreciates the support and patience of its investors during these discussions. conference call: date: thursday, march 16, 2023 time: 10:30 am eastern time participant info: conference id: 9236374 participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 attendee url: https://events.q4inc.com/attendee/683815668 the conference call will be webcast live and available for replay via a link provided in the events section of the company’s ir pages at https://www.immunoprecise.com/investors. please call the conference telephone number five minutes prior to the start time. an operator will register your name and organization. immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@immunoprecise.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the ability to design and to deliver antibodies to address intracellular targets in a safe and effective manner as well as statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the targeted antibodies may be very difficult or impractical to design, develop and deliver, that the integration of in silico models, wet-lab experiments and preclinical studies may not yield the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

the program will leverage biostrand’s lensai® full suite of integrated intelligence technology® with libera bio’s multifunctional polymeric nanocapsules (mpn technology®) the alliance has stipulated a minimum of upfront and downstream milestone payments of usd 155 million plus commercial royalties, per product developed victoria, canada and santiago de compostela, spain, march 15, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), an ai-driven biotherapeutic research and technology company, today announced that talem therapeutics llc, an independently operating subsidiary of ipa, and libera bio s.l., have signed a collaboration agreement to jointly address intracellular targets. it is estimated that 75% of disease-causing targets are located inside cells1. some of the most elusive cancer targets are expressed inside tumor cells. because they are so difficult to address, they have sometimes been deemed “undruggable” and thus represent high unmet medical needs. numerous pathways intersect inside tumor cells, such as the mapk pathway or the “hedgehog pathway”, and may generate conditions for tumors to develop, grow and evade the immune system. disrupting signals at one or more points within these pathways may slow down the growth of the tumors and inhibit their proliferation. small molecules have been successfully developed to this end, but they often present a significant lack of specificity resulting in toxicity, leading to undesirable side effects for patients. engineering antibodies to force them inside tumor cells has also been attempted, but it is a complex process, often wrought with failure. the collaboration between talem and libera bio will leverage a nanotechnology that has been proven in vivo to deliver antibodies inside tumor cells and provides a potential solution to this medical challenge. libera bio’s multifunctional polymeric nanocapsules (mpn technology®) offer an elegant way to deliver antibodies inside tumor cells. the relevant antibodies are encapsulated in multi-layer nanocapsules of approximately 1/10,000th of a millimeter in diameter. the nanocapsules are specifically designed around the physicochemical properties of antibodies, to protect them from degradation in the blood stream. libera bio believes that this might be the only nanotechnology with in vivo proof of concept of delivering whole antibodies intracellularly. in addition, mpns can deliver other biologic modalities or combinations of a biologic and a small molecule in the same nanocapsule. passively or actively targeted, the mpns deliver these compounds through a cell membrane and to intracellular targets. whole antibodies, close to their natural form, can be delivered in this manner. talem will leverage its antibody discovery and development expertise and access, including without limitation, the lensai technology® from biostrand b.v., an independently operating subsidiary of ipa. biostrand has developed a proprietary, ai-driven platform to optimize the design of such antibodies. biostrand computationally generates and rapidly screens a large set of diverse antibody candidates against a prioritized list of targets, including intracellular targets. talem and libera bio will jointly develop novel antibodies for use with mpn delivery, with the goal of offering them to larger pharma companies to conduct late-stage development and commercialization. the work launches with the investigation of two intracellular targets with very high unmet patient needs to offer options to the oncologists treating them. “as we continue to push the boundaries of cancer therapy, the ability to target intracellular proteins has been the 'holy grail' in oncology. libera bio's ground-breaking approach of enabling biologics to penetrate the cell membrane and reach previously 'undruggable' targets is an exciting development that has the potential to transform the way we treat cancer,” said dr. jennifer bath, ceo and president of immunoprecise antibodies ltd. “the libera bio team has been very impressed with the combination of modern in silico tools and wet lab capabilities at the ipa family of companies. we are looking forward to this alliance that just may yield dozens of new options for cancer treatment,” added olivier jarry, co-founder and ceo of libera bio. 1. verdine gl, walensky ld. the challenge of drugging undruggable targets in cancer: lessons learned from targeting bcl-2 family members. clin cancer res. 2007;13(24):7264-70. doi:10.1158/1078-0432.ccr-07-2184. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com about libera bio. s.l. libera bio s.l. (www.liberabio.com) is a private spanish company, spun off from the university of santiago de compostela (galicia, spain). libera bio aims at changing cancer therapy by allowing biologics to cross the cell membrane and reach “undruggable” intracellular targets: the “holy grail” in oncology. it has conducted preclinical studies of antibodies addressing frequent mutations of kras, a protein involved in a large number of cancers, particularly pancreatic, colorectal and lung cancers. it is now preparing for the enabling studies aiming at a clinical trial authorization. visit http://liberabio.com contact: olivier jarry, ceo, contact@liberabio.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the ability to design and to deliver antibodies to address intracellular targets in a safe and effective manner as well as statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the targeted antibodies may be very difficult or impractical to design, develop and deliver, that the integration of in silico models, wet-lab experiments and preclinical studies may not yield the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies